Dimensional Fund Advisors LP Decreases Stock Position in Genmab A/S (NASDAQ:GMAB)

Dimensional Fund Advisors LP lowered its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 35.3% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 45,615 shares of the company's stock after selling 24,894 shares during the period. Dimensional Fund Advisors LP's holdings in Genmab A/S were worth $952,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. EverSource Wealth Advisors LLC increased its stake in shares of Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after acquiring an additional 939 shares in the last quarter. Lindbrook Capital LLC grew its holdings in Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after purchasing an additional 950 shares during the period. Barclays PLC increased its stake in Genmab A/S by 1,072.8% in the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after purchasing an additional 2,285 shares in the last quarter. Cromwell Holdings LLC raised its holdings in shares of Genmab A/S by 656.8% during the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock valued at $60,000 after purchasing an additional 2,496 shares during the period. Finally, R Squared Ltd bought a new position in shares of Genmab A/S during the 4th quarter worth about $93,000. 7.07% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on GMAB. William Blair raised Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. Truist Financial decreased their price objective on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a report on Tuesday, March 11th. BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. Finally, Leerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 target price on the stock in a report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $39.17.

Genmab A/S Stock Up 1.5%

Shares of NASDAQ GMAB traded up $0.30 during mid-day trading on Monday, reaching $20.18. 1,058,340 shares of the company were exchanged, compared to its average volume of 1,111,827. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $30.06. The company's 50 day moving average price is $19.74 and its 200 day moving average price is $20.74. The stock has a market capitalization of $12.94 billion, a PE ratio of 11.60, a PEG ratio of 2.65 and a beta of 1.04.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.08. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. The business had revenue of $715.00 million for the quarter, compared to the consensus estimate of $5.17 billion. On average, sell-side analysts predict that Genmab A/S will post 1.45 earnings per share for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.